Katrina J Curtis1, Victoria M Meyrick1,2, Bhavin Mehta1, Gulam S Haji1, Kawah Li3, Hugh Montgomery3, William D-C Man1,4, Michael I Polkey1, Nicholas S Hopkinson1. 1. 1 National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Trust and Imperial College, London, United Kingdom. 2. 2 Department of Respiratory Medicine, King's College London NHS Foundation Trust, London, United Kingdom. 3. 3 Institute for Sport, Exercise and Health, University College London, London, United Kingdom; and. 4. 4 Harefield Pulmonary Rehabilitation Unit, Harefield Hospital, London, United Kingdom.
Abstract
RATIONALE: Epidemiological studies in older individuals have found an association between the use of angiotensin-converting enzyme (ACE) inhibition (ACE-I) therapy and preserved locomotor muscle mass, strength, and walking speed. ACE-I therapy might therefore have a role in the context of pulmonary rehabilitation (PR). OBJECTIVES: To investigate the hypothesis that enalapril, an ACE inhibitor, would augment the improvement in exercise capacity seen during PR. METHODS: We performed a double-blind, placebo-controlled, parallel-group randomized controlled trial. Patients with chronic obstructive pulmonary disease, who had at least moderate airflow obstruction and were taking part in PR, were randomized to either 10 weeks of therapy with an ACE inhibitor (10 mg enalapril) or placebo. MEASUREMENTS AND MAIN RESULTS: The primary outcome measurement was the change in peak power (assessed using cycle ergometry) from baseline. Eighty patients were enrolled, 78 were randomized (age 67 ± 8 years; FEV1 48 ± 21% predicted), and 65 completed the trial (34 on placebo, 31 on the ACE inhibitor). The ACE inhibitor-treated group demonstrated a significant reduction in systolic blood pressure (Δ, -16 mm Hg; 95% confidence interval [CI], -22 to -11) and serum ACE activity (Δ, -18 IU/L; 95% CI, -23 to -12) versus placebo (between-group differences, P < 0.0001). Peak power increased significantly more in the placebo group (placebo Δ, +9 W; 95% CI, 5 to 13 vs. ACE-I Δ, +1 W; 95% CI, -2 to 4; between-group difference, 8 W; 95% CI, 3 to 13; P = 0.001). There was no significant between-group difference in quadriceps strength or health-related quality of life. CONCLUSIONS: Use of the ACE inhibitor enalapril, together with a program of PR, in patients without an established indication for ACE-I, reduced the peak work rate response to exercise training in patients with chronic obstructive pulmonary disease.
RATIONALE: Epidemiological studies in older individuals have found an association between the use of angiotensin-converting enzyme (ACE) inhibition (ACE-I) therapy and preserved locomotor muscle mass, strength, and walking speed. ACE-I therapy might therefore have a role in the context of pulmonary rehabilitation (PR). OBJECTIVES: To investigate the hypothesis that enalapril, an ACE inhibitor, would augment the improvement in exercise capacity seen during PR. METHODS: We performed a double-blind, placebo-controlled, parallel-group randomized controlled trial. Patients with chronic obstructive pulmonary disease, who had at least moderate airflow obstruction and were taking part in PR, were randomized to either 10 weeks of therapy with an ACE inhibitor (10 mg enalapril) or placebo. MEASUREMENTS AND MAIN RESULTS: The primary outcome measurement was the change in peak power (assessed using cycle ergometry) from baseline. Eighty patients were enrolled, 78 were randomized (age 67 ± 8 years; FEV1 48 ± 21% predicted), and 65 completed the trial (34 on placebo, 31 on the ACE inhibitor). The ACE inhibitor-treated group demonstrated a significant reduction in systolic blood pressure (Δ, -16 mm Hg; 95% confidence interval [CI], -22 to -11) and serum ACE activity (Δ, -18 IU/L; 95% CI, -23 to -12) versus placebo (between-group differences, P < 0.0001). Peak power increased significantly more in the placebo group (placebo Δ, +9 W; 95% CI, 5 to 13 vs. ACE-I Δ, +1 W; 95% CI, -2 to 4; between-group difference, 8 W; 95% CI, 3 to 13; P = 0.001). There was no significant between-group difference in quadriceps strength or health-related quality of life. CONCLUSIONS: Use of the ACE inhibitor enalapril, together with a program of PR, in patients without an established indication for ACE-I, reduced the peak work rate response to exercise training in patients with chronic obstructive pulmonary disease.
Entities:
Keywords:
COPD; exercise; rehabilitation; renin–angiotensin system
Authors: A G Williams; M P Rayson; M Jubb; M World; D R Woods; M Hayward; J Martin; S E Humphries; H E Montgomery Journal: Nature Date: 2000-02-10 Impact factor: 49.962
Authors: William D-C Man; Mohamed G G Soliman; Johanne Gearing; Sheena G Radford; Gerrard F Rafferty; Barry J Gray; Michael I Polkey; John Moxham Journal: Am J Respir Crit Care Med Date: 2003-06-26 Impact factor: 21.405
Authors: Dinesh Shrikrishna; Rebecca J Tanner; Jen Y Lee; Amanda Natanek; Amy Lewis; Patrick B Murphy; Nicholas Hart; John Moxham; Hugh E Montgomery; Paul R Kemp; Michael I Polkey; Nicholas S Hopkinson Journal: Chest Date: 2014-10 Impact factor: 9.410
Authors: Francesca Polverino; Maria E Laucho-Contreras; Hans Petersen; Vanesa Bijol; Lynette M Sholl; Mary E Choi; Miguel Divo; Victor Pinto-Plata; Alfredo Chetta; Yohannes Tesfaigzi; Bartolomé R Celli; Caroline A Owen Journal: Am J Respir Crit Care Med Date: 2017-06-01 Impact factor: 21.405
Authors: Elisabeth Fließer; Anna Birnhuber; Leigh M Marsh; Elisabeth Gschwandtner; Walter Klepetko; Horst Olschewski; Grazyna Kwapiszewska Journal: J Pathol Clin Res Date: 2021-05-12
Authors: Vickram Tejwani; Ashraf Fawzy; Nirupama Putcha; Peter J Castaldi; Michael H Cho; Katherine A Pratte; Surya P Bhatt; David A Lynch; Stephen M Humphries; Gregory L Kinney; Franco R D'Alessio; Nadia N Hansel Journal: Chest Date: 2021-05-21 Impact factor: 10.262
Authors: Sang Wook Kang; Su Kang Kim; Joo-Ho Chung; Hee-Jae Jung; Kwan-Il Kim; Jinju Kim; Ju Yeon Ban Journal: Biomed Res Int Date: 2016-10-18 Impact factor: 3.411
Authors: Samantha S C Kon; Caroline J Jolley; Dinesh Shrikrishna; Hugh E Montgomery; James R A Skipworth; Zudin Puthucheary; John Moxham; Michael I Polkey; William D-C Man; Nicholas S Hopkinson Journal: BMJ Open Respir Res Date: 2017-03-08